Skip to content
Moffitt Cancer Center· @MoffittNews · X·· 2026-04-21Score60
Body · original

At #AACR26, Dung-Tsa Chen, PhD, highlights how early, low-grade side effects may serve as biomarkers to predict treatment response in advanced NSCLC. #MoffittAACR26
@AACR

Heat 8 · 6 likes · 0 replies · 2 reposts

Source: Moffitt Cancer Center · x.com

CBACBA Frontier Insights (CFI)Chinese Biopharmaceutical Association (CBA)www.cba-usa.org